Member Info for CHELSEA7

With so much more to come................................

20-May-19 07:00 RNS-R Scancell and CRUK provide an update on SCIB2
10-May-19 07:00 RNS-R Clinical Advisory Board and Update on Modi-1
25-Apr-19 07:00 RNS UK approval to start SCIB1 Phase 2 trial
08-Apr-19 07:00 RNS-R Japan patent for Moditope immunotherapy platform
21-Mar-19 07:00 RNS-R Professor Lindy Durrant receives Waldenström award
20-Mar-19 07:00 RNS Scancell strengthens IP portfolio

Will take now over 200k shares at 4.605

Buys 322k

12 Trades

Will take 180k at 4.605..........................gradually increasing

Buys 298k (54 mins)

At 4.5p....................tick up coming?

157.166k

Nice average too. There is certainly enough news due to keep it flowing .ATB

All buys

Will take 170k at 4.55

GL smpunter. WINS very active on bid/ask all week

50k

Tick Up 4.5/5 + 11.76%

4.2/5 + 8.24%

Opening 5p, 1 MM to go.

Grouping 4/5

WINS 4.2
CFEP 4.5 Still to be declared

Crumbs, hence why I said the likelihood of three trials in 2020 is becoming realistic

Just CFEP on 4.5 now, haven"t opened yet as another 5 MMs

Scancell and CRUK provide an update on SCIB2
Mon, 20th May 2019 07:00
RNS Number : 4804Z
Scancell Holdings Plc
20 May 2019
20 May 2019

Scancell Holdings Plc

("Scancell" or the "Company")

Scancell and Cancer Research UK provide an update on the development of SCIB2, a novel cancer immunotherapy

SCIB2 to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial

Scancell Holdings PLC, a developer of novel immunotherapies for the treatment of cancer, and Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research, are pleased to provide an update on their clinical development partnership* for the development of Scancell's ImmunoBody® vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC).

Scancell's ImmunoBody® immunotherapy platform activates the body's immune system by enhancing the uptake and presentation of cancer antigens to help target and eliminate cancer cells. SCIB2, Scancell's second ImmunoBody® therapy, targets an antigen called NY-ESO-1, which is expressed on a range of solid tumours, including NSCLC, oesophageal, ovarian, bladder and prostate cancers, neuroblastoma, melanoma and sarcoma.

Ratty, yeah i like that a lot, especially the comments by Blackburn of CRUK. Well we were due an update on SCIB2, and still we have a lot of news to come. The tide is changing as each RNS gets better and takes us nearer to clinical trials, our ultimate goal. Think we can workout expected timelines, and for newbies remember CRUK are funding this trial fully.

4.2

6 MMs to follow.

Bobbust?

No not really, we have been wanting toknow at what stage we are with SCIB2, I think that answers that, and was the natural progression we expected.

Fancied a blue day anyway with the bid closing up on the spread. Heres to a great day and yes the prospect of three trials running in 2020 gets a whole load closer.